ecrin-mdr-crcClinical2023IPD Sharing (as of July 2023): NoColorectal NeoplasmsColorectal Cancer MetastaticColorectal NeoplasmsColorectal Cancer MetastaticInterventionalhttps://newmdr.ecrin.org/Study/2751724China6Antineoplastic Agents, ImmunologicalImmunoglobulinsAntibodiesAntibodies, MonoclonalECRIN MDRSuspendedfalseEvaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients With mCRCThis study is a phase II study to evaluate the efficacy, safety and tolerability of HLX26 and HLX10 in the treatment of patients with metastatic colorectal carcinoma that had received 3 prior therapies.2023-06-152751724NCT05584137